Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

NCT02420860 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

113

Enrollment

OTHER

Sponsor class

Conditions

Hematopoietic Cell Transplantation Recipient
Plasma Cell Myeloma

Interventions

BIOLOGICAL: Elotuzumab
DRUG: Lenalidomide
OTHER: Questionnaire Administration

Sponsor

M.D. Anderson Cancer Center

Collaborators

National Cancer Institute (NCI)